Can smarter technology selection help de-risk small-molecule development?
How early identification of solubility, permeability and solid-state risks can prevent costly reformulation and manufacturing problems.
Sponsored
Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity
Leading CDMO to attend CPHI Milan 2026 in Italy
Beyond OEB5: Is OEB6 really the next standard for high-potency pharma?
Oral solid dose at a turning point: Scaling for the next generation of therapies
How China’s rise as a biopharma innovation hub is reshaping global dealmaking strategies
Why Most FDA Warning Letters Share a Single — and Fixable — Root Cause
What drives time-to-randomization in oncology trials?
